论文部分内容阅读
98例病人随机分成A组、B组、C组。A、B组分别用伊贝沙坦、凯时,C组联用伊贝沙坦、凯时,疗程均为3个月,观察治疗前后收缩压(SBP)、舒张压(DBP)、尿微量白蛋白/肌酐(MA/Cr)、糖化血红蛋白(HbA1C)、血肌酐(Scr)、肌酐清除率(Ccr)、2β微球蛋白(2β-MG)、尿葡萄糖苷酶(NAG)等相关指标变化。结果:C组治疗前后Scr、β2MG、NAG均较A、B两组有明显下降,Ccr明显升高,C组与A、B两组之间有显著差异(P<0.05)。结论:凯时与伊贝沙坦联合应用治疗早期糖尿病肾病较单一应用疗效好。
98 patients were randomly divided into A group, B group, C group. A, B were treated with irbesartan, Kay, C combined with irbesartan, Kay, the treatment were 3 months, before and after treatment to observe the systolic blood pressure (SBP), diastolic blood pressure (DBP) Serum albumin / creatinine (MA / Cr), HbA1C, Scr, Ccr, 2β-MG, NAG and other related indicators . Results: The levels of Scr, β2MG and NAG in group C before and after treatment were significantly lower than those in groups A and B, and Ccr was significantly increased. There was significant difference between group C and groups A and B (P <0.05). Conclusion: The combination of Kay and irbesartan in the treatment of early diabetic nephropathy is better than single application.